Zydus Cadila gets final USFDA nod to HIV infection drug Atazanavir
Atazanavir, an antiretroviral drug, is used to treat infection of the Human Immunodeficiency Virus (HIV);
Advertisement
Ahmedabad: Zydus Cadila has received final approval from the USFDA to market Atazanavir Capsules (US RLD: ReyatazTM Capsules) in the strengths of 150 mg, 200 mg, and 300 mg.
Atazanavir, an antiretroviral drug, is used to treat infection of the Human Immunodeficiency Virus (HIV).
It is used in combination with other antiretroviral drugs to treat HIV-1 infection.
The drug will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.